Across TCGA pan-cancer cohorts, IGHV1OR15-9 Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated IGHV1OR15-9 data layer compared with 23 for mass-spec protein and 2 for mass-spec protein.
The strongest signal is observed in esophageal carcinoma (ESCA), where higher IGHV1OR15-9 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated IGHV1OR15-9 expression acts as an unfavorable survival marker.
ESCA, GBM, and STAD are the cancer types where IGHV1OR15-9 Mutation most reproducibly stratifies survival.
Mutation survival associations by lineage
Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.